论文部分内容阅读
为了观察 APP17肽对糖尿病小鼠 Tau蛋白 Ser2 0 2 / Thr2 0 5磷酸化的影响 ,用链脲佐菌素 (选择性地破坏胰岛β-细胞 ,导致糖尿病 )诱发小鼠糖尿病模型 ,并皮下注射 APP17肽 ( β-淀粉样肽前体蛋白 3 19～ 3 3 5 )给予治疗。 4周后取脑组织进行 AT-8(抗 Ser2 0 2 / Thr2 0 5特异单抗 )免疫组化反应。结果证明 :糖尿病组 AT-8阳性反应细胞广泛分布于压后颗粒皮层、海马、丘脑、下丘脑等部位 ,而正常对照组及 APP17肽治疗组仅在压后颗粒皮层、海马可见阳性反应细胞 ,且着色淡。本研究提示 ,糖尿病脑内多个区域的神经元存在较多的 AT-8阳性细胞 ,而 APP17肽可使 AT-8阳性反应细胞出现的部位和数量正常化。
To observe the effect of APP17 peptide on Tau protein Ser2 0 2 / Thr205 phosphorylation in diabetic mice, diabetic mice were induced with streptozotocin (which selectively destroyed islet β-cells, resulting in diabetes) and injected subcutaneously APP17 peptide (β-amyloid precursor protein 3 19 ~ 3 3 5). After 4 weeks, the brain tissue was harvested for AT-8 (anti-Ser2 0 2 / Thr2 05 specific monoclonal antibody) immunohistochemistry. The results showed that AT-8 positive cells in diabetic group were widely distributed in the cortex, hippocampus, thalamus, hypothalamus and other parts of the diabetic group, while the normal control group and APP17 peptide treatment group only positive cells in the pressure cortex and hippocampus, And pale color. This study suggests that there are many AT-8 positive neurons in multiple regions of brain of diabetic patients, while APP17 peptide can normalize the location and number of AT-8 positive cells.